Topical Ruxolitinib Versus Tacrolimus With Excimer Laser for Localized Vitiligo
Key facts
- Who runs it
- Kafrelsheikh University
- Where
- Kafr ash Shaykh, EgyptSee the site
- Trial code
- Status
- Enrolling by invitation
- People taking part
- 40 people, planned
- Started
- 1 Jul 2026
- Expected to end
- 1 Jan 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Tacrolimus 0.1% ointment
- Ruxolitinib 1.5% cream
- 308-nm excimer laser
- Record updated
- 2 November 2026
Who can take part
- Age
- 12 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Stable localized non-segmental facial vitiligo
- Age 12 years or older
- Nonsmoker
- No vitiligo treatment during the preceding 6 months
- Selected lesion surface area less than 20 cm2
Who cannot take part
- Vitiligo treatment within the previous 6 months
- Diabetes mellitus
- Collagen vascular disease or other autoimmune disease
- Relevant systemic illness, other skin disease, drug allergy, or contraindication identified during screening
- Pregnancy or lactation
Where in Egypt
- Kafrelsheikh University HospitalKafr ash Shaykh, EgyptNo longer taking part
About the trial
What the trial wants to find out
This randomized comparative study will evaluate the efficacy and safety of topical ruxolitinib 1.5% cream compared with topical tacrolimus 0.1% ointment, each combined with 308-nm excimer laser therapy, in patients aged 12 years or older with stable localized non-segmental facial vitiligo. Forty participants will be randomly assigned in a 1:1 ratio to receive one of the topical treatments twice daily for 24 weeks plus excimer laser treatment. Clinical, dermoscopic, patient-reported, and histopathological outcomes will be assessed before and after treatment, with follow-up for recurrence.
The 2 groups in the trial
- Tacrolimus plus excimer laserExisting treatment, for comparison
Tacrolimus 0.1% ointment applied twice daily for 24 weeks, plus 10 sessions of 308-nm excimer laser therapy administered twice weekly.
Treatment: Tacrolimus 0.1% ointment and 308-nm excimer laser
- Ruxolitinib plus excimer laserTreatment being tested
Ruxolitinib 1.5% cream twice daily for 24 weeks plus 10 sessions of 308-nm excimer laser therapy, twice weekly.
Treatment: Ruxolitinib 1.5% cream and 308-nm excimer laser
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Clinical and Histopathological Evaluation of Excimer Laser With Topical Ruxolitinib 1.5% or Tacrolimus 0.1% in Localized Vitiligo: A Randomized Comparative Study
- Record updated
- 2 November 2026